
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos is a leader in the ophthalmic pharmaceutical and medical technology market, offering a unique solution for the treatment of glaucoma, corneal disorders, and retinal diseases with its dropless therapy iDose TR. Despite potential uncertainty surrounding proposed changes in reimbursement policy, Glaukos is well-positioned for continued revenue growth from a diverse portfolio of products, including iStent and iDose TR, and the potential for Epioxa to significantly contribute to revenue in the future. With a solid pipeline, strong execution potential, and a competitive market position, Glaukos's stock presents an attractive investment opportunity.
Bears say
Glaukos is facing some potential headwinds in its iDose sales due to the proposed LCD, which may result in a -25% impact to iDose volumes on a weighted average basis for CY25 volumes. Additionally, there is potential for a -10% or -$30M of iDose revenue in CY27. Despite this, there are potential offsets for iDose from other sources such as Medicare Advantage patients and the Epioxa launch, but the impact on iDose is still a concern. There is also some potential downside risk in the bear case scenario, but overall, the outlook for Glaukos is still strong with a focus on innovative therapies for glaucoma, corneal disorders, and retinal diseases.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares